Multiple Sclerosis – Access & Reimbursement – Access & Reimbursement – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market continues to evolve as each new approved disease-modifying therapy (DMT) further expands treatment choice. The most recent launches have entered established drug classes, but several novel emerging drugs—including Bruton’s tyrosine kinase (BTK) inhibitors, frexalimab, and vidofludimus calcium / IMU-838—are poised to bring new mechanisms of action and potentially address gaps in treatment (e.g., for underserved nonrelapsing progressive MS patients). For payers and prescribers to be receptive to these treatments, they will have to demonstrate meaningful differentiation. Meanwhile, the deepening impact of oral generic DMTs may increase the reimbursement challenges faced by new drugs, especially in the relapsing MS space. For developers bringing DMTs to market, understanding the current and future access landscape will be key for optimal uptake.
Questions Answered
- What is the coverage status of key brands on commercial plans?
- How do DMTs’ cost and payer restrictions influence clinical decision-making in MS today?
- How receptive are surveyed neurologists and payers to key novel and next-in-class agents?
- How is generics competition affecting coverage and prescribing in the MS market?
- What coverage and uptake are expected for Sanofi’s tolebrutinib and frexalimab, as well as Roche’s fenebrutinib? What clinical and nonclinical differentiators would drive preferential use and coverage terms?
Product Description
Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:
- Identify and learn how to overcome roadblocks to market access to best position your brand.
- Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
- Evaluate competitor strategies for securing favorable market access terms.
Markets covered: United States.
Primary research:
- Survey of 100 U.S. neurologists.
- Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Immunic Therapeutics, Merck, Novartis, Roche / Genentech, Sandoz, Sanofi, TG Therapeutics, Vanda, Viatris / Mapi Pharma.
Key drugs: Aubagio / teriflunomide, Briumvi, Bafiertam, Copaxone / glatiramer acetate, Gilenya / fingolimod, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera / dimethyl fumarate, Tysabri, Tyruko, Vumerity, Zeposia, BTK inhibitors, Frexalimab, GA Depot, IMU-838.
Content highlights:
- Reimbursement and contracting.
- Access and prescribing.
- Opportunities and challenges for emerging therapies.
- Disease-specific special topics.
